Novavax | NVAX - Ebitda


Novavax reported $19.36M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Adma Biologics USD 61.07M 12.52M Mar/2026
Agenus USD -10.11M 19.02M Mar/2025
AstraZeneca USD 5.16B 510M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Geron USD 3.83M 25.12M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
MannKind USD 2.93M 5.98M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -1.26B 468M Mar/2026
Novartis USD 5.41B 431M Mar/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.01B 18M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
TG Therapeutics USD 26.9M 1.21M Jun/2026